相关实验视频
Updated: May 11, 2025
09:16
Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
17.4K
保护功能:草甘,GLP1激动剂和抗阿尔多斯类药物
1UOC of Cardiology, Policlinico Casilino, via Casilina, 1049, 00169 Rome, Italy.
概括
新的药物,如gliflozins和incretins减缓慢性病 (CKD) 的进展,降低心血管风险. 芬也在治疗糖尿病患者的CKD和心血管结果方面表现有前途.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性病 (CKD) 是一个日益严重的全球健康问题,几十年来治疗选择有限.
- 功能逐渐下降会增加心血管风险,导致心脏病发作,中风,心力衰竭和死亡率.
- 传统的CKD治疗,包括风险因素控制和氨酸-血管酶-阿尔多斯特系统阻断,其疗效有限.
研究的目的:
- 审查最近的治疗进展对减缓CKD进展的影响.
- 突出与新型CKD治疗相关的心血管益处.
- 讨论新药类在治疗CKD和相关心血管风险方面的作用.
主要方法:
- 审查最近的临床试验和关于CKD治疗的指导方针更新.
- 对gliflozins,incretins和矿物质皮质体受体对手 (如finerenone) 的数据的分析.
- 用这些新型药物治疗的患者心血管和结局的评估.
主要成果:
- 格利弗洛辛和因克雷丁在减缓糖尿病和非糖尿病患者中CKD进展方面已经证明有效.
- 这些药物类别显著减少心血管事件和死亡率.
- 芬龙是一种新型矿物质皮质类受体对抗剂,在糖尿病患者的第三期试验中显示出显著的心血管和功能益处.
结论:
- 新型药物类别,包括gliflozins,incretins和finerenone,代表了CKD管理中的范式转变.
- 这些药物在减缓功能衰退和减轻心血管风险方面提供了巨大的好处.
- 目前的指导方针正在不断发展,以纳入这些有效的疗法,以改善患者的治疗结果.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
125
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
125
01:25Antihypertensive Drugs: Direct Renin Inhibitors
440
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
440
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
401
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
401
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
136
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
136
01:24Glucagon-like Receptor Agonists
261
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
261
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305